Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers
Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if a new investigational drug called Panobinostat
is safe, tolerable and to obtain an initial assessment of efficacy, when given in combination
with Sorafenib for the treatment of certain types of lung cancer, kidney cancer and soft
tissue sarcoma.